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Effects of lipid-lowering drugs on intermediate-density lipo- production, delayed catabolism of VLDL into IDL, sup-
protein in uremic patients. pressed conversion of IDL to LDL, and reduced clear-
Background. Patients with chronic renal failure often have
ance of LDL from the circulation. These metabolic alter-alterations in lipoprotein profile including elevated very-low
ations are attributable to suppressed lipolysis mediateddensity lipoprotein (VLDL) and intermediate density lipopro-
tein (IDL), and reduced high density lipoprotein (HDL) levels. by lipoprotein lipase (LPL) and hepatic triglyceride li-
Among these changes, raised IDL has been shown as an inde- pase (HTGL), and to decreased activity of the LDL
pendent risk factor for atherosclerosis in hemodialysis patients.
receptors as outlined in Figure 1.There are a limited number of studies reporting pharmacologi-
cal approaches to IDL reduction in a uremic population.
Methods. We therefore summarize the effects of lipid-lower-
ing drugs on IDL levels in patients with chronic renal failure ATHEROGENIC LIPOPROTEINS IN
treated by hemodialysis (HD) or continuous ambulatory peri- DIALYSIS PATIENTStoneal dialysis (CAPD).
Results. First, a nicotinic acid analog niceritrol was given to Atherosclerosis is more advanced in uremia. Intima-
hemodialysis patients. The drug increased HDL-cholesterol by medial thickness of carotid and femoral arteries is greater
11%, but the reductions in VLDL-, IDL- and LDL-cholesterol
in hemodialysis patients than in the age- and gender-were not significant. Second, CAPD patients were treated with
matched healthy controls [5]. The sclerotic changes ofa fibric acid derivative clinofibrate, which was excreted mainly
into bile unlike other drugs in this class. The fibrate resulted the aorta are also more advanced in hemodialysis pa-
in a remarkable reduction in VLDL-triglycerides, although it tients [6]. Although uremic dyslipidemia is believed to
did not reduce IDL-cholesterol. Finally, an HMG-CoA reduc-
contribute to an increased risk for atherosclerosis, it istase inhibitor (statin) pravastatin was used in HD and CAPD
not known which lipoprotein abnormality is most closelypatients. Pravastatin reduced IDL- and LDL-cholesterol to the
same extent (by 31%). None of these treatments caused serious related to atherosclerosis. Our recent study indicated that
adverse effects. IDL is a significant and independent risk factor for scle-Conclusions. We propose that IDL is an important target
rotic changes of the aorta in the hemodialysis populationin the management of uremic dyslipidemia. To date, statins
have been shown to be suitable for this purpose, although it [6]. Raised IDL is an important risk factor not only in
remains to be clarified whether such an intervention reduces dialysis patients but also in the general population [7].
the risk for atherosclerotic vascular events in the uremic popu- In our previous study, 45% of nondiabetic hemodialysislation.
patients exceeded 15 mg/dl of IDL-cholesterol, the 95th
percentile level of nonuremic healthy population [1].
Patients with chronic renal failure show hypertriglyc-
eridemia due to raised levels of very-low density lipopro-
STRATEGIES TO REDUCE THE IDL LEVELtein (VLDL) and intermediate density lipoprotein (IDL)
[1]. Low density lipoprotein (LDL) concentration is not Theroretically, the following approaches could reduce
usually elevated but rather lower than that of nonuremic plasma IDL levels: (1) suppression of hepatic production
control subjects [1]. High density lipoprotein levels are of VLDL, the precursor of IDL; (2) promotion of IDL-
reduced in renal failure [1, 2]. In vivo kinetic studies to-LDL conversion; and (3) enhancement of the LDL
in renal failure patients [3, 4] indicated normal VLDL receptor activity. Nicotinic acid, fibrates, and HMG-CoA
reductases (statins) are suitable for these purposes, re-
spectively. There are only a limited number of studiesKey words: cholesterol, uremia, statin, nicotinic acid, hemodialysis,
fibrate, CAPD. that examined the effects of lipid-lowering drugs on raised
IDL in patients with chronic renal failure (Table 1). 1999 by the International Society of Nephrology
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Table 1. Reports on the effects of lipid-lowering drugs on intermediate density lipoprotein (IDL) levels in uremic patients
IDL-cholesterol
Drug name Daily dose Subjects Baseline level Reduction Reference
Niceritrol 750 mg HD (N 5 17) 12.4 mg/dl 19%a [9]
Clinofibrate 600 mg CAPD (N 5 12) 21.1 mg/dl 9%a [10]
Pravastatin 10 mg HD (N 5 11) 14.3 mg/dl 34% [11]
10 mg CAPD (N 5 8) 22.8 mg/dl 29% [11]
10 mg HD1CAPD (N 5 19) 17.9 mg/dl 31% [11]
Abbreviations are: HD, hemodialysis; CAPD, continuous ambulatory peritoneal dialysis.
a Not statistically significant
triglycerides by 48% in patients on CAPD [9]. LDL-
cholesterol increased following clinofibrate treatment,
suggesting that the VLDL-IDL-LDL delipidation cas-
cade might improve with this treatment. However, no
change was observed in IDL-triglycerides or IDL-choles-
terol.
EFFECTS OF STATINS ON IDL
HMG-CoA reductase inhibition by statins results in
suppressed cholesterol biosynthesis, reduced intracellu-
lar cholesterol pool, and up-regulation of the LDL recep-Fig. 1. Metabolic pathway of intermediate density lipoprotein (IDL)
tor expression. The LDL receptor recognizes not onlyand strategies to reduce IDL level. Very-low density lipoprotein
(VLDL), the precursor of IDL, is produced by the liver. VLDL is LDL, but partly delipidated VLDL and IDL as well.
metabolized to IDL by the action of lipoprotein lipase (LPL). IDL is Treatment with 5 to 10 mg pravastatin per day in hemodi-further converted to low density lipoprotein (LDL) by hepatic triglycer-
alysis and peritoneal dialysis patients resulted in markedide lipase (HTGL). LDL and a portion of IDL particles are cleared
from the circulation via the LDL receptors (LDL-Rc) expressed in the reduction in VLDL-, IDL-, and LDL-cholesterol levels
liver (70%) and other cells (30%). Patients with chronic renal failure [10]. The reduction of IDL by 31% was as great as thatshow normal VLDL production, delayed catabolism of VLDL into
of LDL-cholesterol. Simvastatin, another HMG-CoA re-IDL, impaired conversion of IDL to LDL, and reduced clearance of
LDL from the circulation. As a result, they have a raised level of VLDL ductase inhibitor, was also shown to be effective in de-
and a decreased level of LDL. IDL concentration is markedly elevated creasing cholesterol-rich fraction of VLDL, presumablyin renal failure. There are three approaches to the reduction of IDL:
VLDL-remnant.(1) suppression of hepatic production of VLDL; (2) promotion of IDL-
to-LDL conversion; and (3) enhancement of the hepatic LDL-Rc activ-
ity. Nicotinic acid, fibrates, and HMG-CoA reductases (statins) are
suitable for these purposes, respectively. CONCLUSIONS
We propose that the reduction in IDL should be an
important target in the management of uremic dyslipide-
mia, because IDL was shown to be an independent riskEFFECTS OF NICOTINIC ACIDS ON IDL
factor for atherosclerosis in uremic patients as well as
Nicotinic acids suppress hepatic secretion of VLDL. in the general population. To date, the only drugs clearly
When a nicotinic acid analog niceritrol was adminis- shown to reduce IDL levels in chronic renal failure effec-
trated to hemodialysis patients at a daily dose of 750 mg, tively and safely are statins. It remains to be clarified
IDL-cholesterol was decreased by 19%, but this was whether such an intervention reduces the risk for athero-
not statistically significant [8]. Interestingly, it decreased sclerotic vascular complications in the uremic population.
lipoprotein(a) [Lp(a)] concentration by 33% and in-
creased HDL-cholesterol by 11%. Reprint requests to Yoshiki Nishizawa, M.D., Professor, Second De-
partment of Internal Medicine, Osaka City University Medical School,
1-4-3, Asahi-machi, Abeno-ku, Osaka 545-8585, Japan.
E-mail: m6413203@med.osaka-cu.ac.jpEFFECTS OF FIBRATES ON IDL
In contrast to most other fibrates that are metabolized
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